News Alert on: 3M Co (NYSE:MMM), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Range …

On Wednesday, 3M Co (NYSE:MMM)’s shares inclined 1.98% to $141.24.

Health care providers must protect sensitive data even as changing practices demand that it be more mobile and easily accessible. In response, the Visual Privacy Advisory Council (VPAC), a 3M-sponsored group of data privacy and security thought leaders dedicated to raising awareness on the issue of visual hacking, has selected health care security and privacy expert Kate Borten as its newest member.

The “Fifth Annual Benchmark Study on Patient Privacy and Data Security” released by the Ponemon Institute and sponsored by ID Experts this year revealed that 90 percent of health care organizations practiced at least one data breach in the past two years, while nearly 40 percent practiced more than five breaches. In addition to putting patient data at risk, breaches in healthcare can be costly, with the average cost of a data breach for healthcare organizations estimated to be more than $2.1 million, cited Dr. Larry Ponemon, founder of the Ponemon Institute and chairman of the VPAC.

In addition to being a nationally recognized expert in health information security and privacy, Borten is the founder and president of The Marblehead Group, a consultancy group dedicated to privacy and information security primarily within the health care industry. Her previous experience comprises the establishment of security programs at Massachusetts General Hospital and Beth Israel Deaconess Medical Center/CareGroup in Boston.

3M Company operates as a diversified technology company worldwide. Its Industrial segment offers tapes; coated, non-woven, and bonded abrasives; adhesives; ceramics; sealants; specialty materials; filtration products; closure systems for personal hygiene products; acoustic systems products; automotive components; abrasion-resistant films; structural adhesives; and paint finishing and detailing products. The company’s Safety and Graphics segment provides personal protection products; traffic safety and security products; commercial graphics systems; commercial cleaning and protection products; floor matting; and roofing granules. Its Electronics and Energy segment offers optical films; packaging and interconnection devices; insulating and splicing solutions for the electronics, telecommunications, and electrical industries; touch screens and monitors; renewable energy component solutions; and infrastructure protection products.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s shares dropped -5.70% to $6.62.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, recently declared publication of results from the pivotal clinical study for EVOMELA, used for myeloablative conditioning in multiple myeloma (MM) patients undergoing autologous transplantation. (ASCT). The study, led by Dr. Parameswaran Hari from Froedtert Hospital and Medical College of Wisconsin, was published in the Biology of Blood and Marrow Transplantation (BBMT) journal.

The BBMT journal publication comprises data on 61 patients who were enrolled in this open-label Phase 2b pivotal study at five US study sites; 56 patients had newly diagnosed disease and five had relapsed MM following preceding ASCT. Patients enrolled in this study received 200 mg/m2 of EVOMELA as two doses on Day -3 and Day -2 preceding to ASCT (Day 0). Efficacy was assessed by clinical response at Day +100 with an ORR of 95% and CR rate of 31% (16% stringent CRs) based on investigators’ assessments, and rates of 100% and 21%, respectively based on independent pathology review; the lower rate of confirmed CRs in the independent review was due to missing data. Importantly, the five patients who had formerly relapsed from a preceding ASCT were all shown to achieve a response to EVOMELA. All patients in the study achieved myeloablation with a median of 5 days post-ASCT, and all patients had successful neutrophil and platelet engraftment (median of 12 days and 13 days post-ASCT, respectively). Treatment-related mortality was 0%, and non-hematologic adverse events were mostly Grade 1 and Grade 2 in severity. The incidence of Grade 3 mucositis and Grade 3 stomatitis were 10% and 5%, respectively with no Grade 4 mucositis or stomatitis stated. Twenty percent of patients practiced treatment-emergent serious adverse events, most of which were Grade 3, and comprised of events commonly stated in patients undergoing myeloablative chemotherapy; no new safety signals were identified.

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL. It is also developing Captisol-enabled MELPHALAN, an intravenous formulation for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia.

At the end of Wednesday’s trade, Range Resources Corp. (NYSE:RRC)‘s shares surged 0.32% to $38.08.

RANGE RESOURCES CORPORATION (NYSE: RRC) recently declared that its Board of Directors declared a quarterly cash dividend on its common stock for the third quarter. A dividend of $0.04 per common share is payable on September 30, 2015 to stockholders of record at the close of business on September 15, 2015.

Range Resources Corporation, an independent natural gas, natural gas liquids (NGLs), and oil company, engages in the acquisition, exploration, and development of natural gas and oil properties in the United States. It holds interests in developed and undeveloped natural gas and oil leases in the Appalachian and Midcontinent regions.

Allstate Corp (NYSE:ALL), ended its Wednesday’s trading session with 1.38% gain, and closed at $57.93.

The Allstate Corporation (ALL), the nation’s largest publicly held personal lines insurer, declared that Thomas J. Wilson, its chairman and chief executive officer, will present at the Barclays Global Financial Services Conference at 8:15 a.m. Eastern Time on Thursday, September 17.

The Allstate Corporation, through its auxiliaries, engages in the property-liability insurance and life insurance businesses in the United States and Canada. The company’s Allstate Protection segment sells private passenger auto and homeowners insurance products under the Allstate, Encompass, Esurance brand names.


This article is published by The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

Leave a Reply

Notify of